Drug Trial Radar · NCT05174637
A Study of FDA018-ADC in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Oct 22, 2021
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with advanced/metastatic solid tumors.
Conditions
- Advanced/ Metastatic Solid Tumors
Interventions
FDA018-ADCDrug
Subjects will receive an intravenous infusion of FDA018-ADC until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The dose limiting toxicity ( DLT)Time frame: From first dose to the end of Cycle 1, up to 35 days.
- The maximum tolerated dose (MTD)Time frame: From first dose to the end of Cycle 1, up to 35 days.
- Adverse EventsTime frame: From subject randomization up to 60 months
- Objective Response Rate (ORR) according to RECIST 1.1Time frame: From subject randomization up to 60 months.
- Recommended phase II dose (RP2D)Time frame: From subject randomization up to 60 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.